Genmab — Juli 2018
-
Det handler KUN om penge: " The committee agreed that the
improvements in progression-free survival with daratumumab plus
bortezomib and dexamethasone are large and that this combination is a
step-change in the treatment of people with multiple myeloma...... -
Og så videre: The committee
understood from patient and clinical experts, and the Cancer Drugs Fund
clinical lead, that an 18-month improvement in median progression-free
survival was considered a ‘game-changing’ treatment effect in the secondline
treatment of multiple myeloma. It concluded that daratumumab plus
bortezomib and dexamethasone had a statistically significant and clinically
important effect on progression-free survival compared with bortezomib
plus dexamethasone. -
@E L
Why is August 2nd important -
only because it is the Closing date for comments for this decision for NICE https://www.nice.org.uk/guidance/indevelopment/gid-ta10174/consultation/html-content-2
-
"14.07" bedre anbefaling fås ikke.
-
...men vi har da ikke nået pfs i de studier endnu?
-
At AQR reducerer er vel også en positiv trigger.
-
Teknisk er vi også gået i bekræftet uptrend igen med brud
af 1.020.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind